In September, patients with multiple sclerosis (MS) received the welcome news that the U.S. Food and Drug Administration (FDA) had approved a promising new drug for their condition called Gilenya.
Now, a team from The Scripps Research Institute has discovered that this drug’s success may involve an unexpected biological mechanism acting within the central nervous system (CNS). This difference may mean that Gilenya offers even more benefits than previously realized and would represent the first MS therapy with direct CNS activities.
“This drug could make a big difference to MS patients,” says Jerold Chun, M.D., Ph.D., a professor in the Department of Molecular Biology and member of the Dorris Neuroscience Center at Scripps Research. “And these results are going to make doctors and scientists consider CNS mechanisms in MS therapies, as they follow patients being treated with Gilenya.”... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309